Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Shots:

• Silence to receive $20M up front, $10M as research milestone for SLN500 + for each of the two optioned assets, ~$663M including clinical, regulatory and commercial milestones and royalties on net sales for SLN500. Silence will also receive funds for P-I development including GMP⁴ manufacturing and will be responsible for all pre-clinical activities and for executing development program of each asset until the end of P-1   
• Mallinckrodt to get exclusive WW rights for Silence’s SLN500 candidate with an option to license up to two additional pre-clinical RNAi assets and will be responsible for all clinical development and global commercialization. If the option is executed, Silence will receive up to $703M/asset for clinical, regulatory & commercial milestones on each optional asset plus royalties
• Silence’s SLN500 is a C3-targeting RNAi therapeutic pre-clinical candidate involved in targeting specific protein in the complement pathway  

Click here to read full press release/ article | Ref: Mallinckrodt Pharmaceuticals | Image: Behnace